PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Case Study

Volume 4 Issue 3

Symptomatology of Mpox Disease and Implications for Surveillance in Imo State, Nigeria

Adeniran Adeniyi A*, Eronini Ebubechi C, Olugbenga Asaolu, Simisola Adedeji, Ugwu, Adaeze Joy, Marcus Oluwadare, Faith Ehiaghe Ugba, Aibinuomo Ayomide Oluwaseyi, Tella Adedamola, Dania Oluyinka, Olayiwola Olanike Suliat, Oladele Tinuola, Daniel Musa Haruna, Adebayo O Amao, John O Ibitoye, Oluwagbemiga Obembe, Christopher Obanubi and Abdulmalik Abubakar

February 09, 2024

DOI : 10.56831/PSMPH-04-126

View PDF

Abstract

Mpox disease, caused by Mpox virus, a double-stranded DNA virus, genus Orthopoxvirus of the family Poxviridae has an incubation period of 6 to 13 days but can range from 5 to 21 days. The symptoms are quite diverse and this makes a number of rash-associated illnesses close differential diagnosis. This study aims to review the common symptoms associated with the disease during outbreaks in Imo State between 2017 and 2023 and the implications for surveillance.

Surveillance data from the Surveillance Outbreak Response Management and Analysis System (SORMAS) was extracted between January 2017 and December 2023 across the 27 Local Government Areas (LGAs) of Imo State. A line list of 231 suspected cases was downloaded into an excel template and analyzed using SPSS ® version 20 software. Analysis was done using descriptive statistics and associations were tested using Fischer’s exact at 0.05 level of significance.

Of the 231 suspected cases, 57.1% (132) were males, 42.9% (99) were females and the modal age group was between the ages of 0-4 (32.5%). About one-fifth (21.2%, n = 49) were confirmed positive, 27 males (55.1%) and 22 females (44.9%), (p>0.05). Modal age group was 20-24 (22.4%, n=11), 18% (9) were children under 14 years, p>0.05.

Fever was a constant presentation with 68.4% (n=158) and 65.3% (n=32) of suspected and confirmed cases respectively presented with varying degrees of fever. Other modes of presentation among the confirmed cases are conjunctivitis (12.2%, n=6), cough (16.3%, n=8), photosensitivity (14.3%, n=7), fatigue (36.7, n=18 and headache (45%, n=22). Only 5.6% and 4% of suspected and confirmed cases, respectively, had knowledge of contact with an infectious source. Only 12.2% (n=6) presented with one form of lymphadenopathy contrary to literature. This might be associated with the clinical skills of the cadre of health workers who are responsible for surveillance activities at the LGA (district) level in the State. This study has been able to describe the symptomatology of Mpox during outbreaks between 2017 and 2023 Imo State. The findings have significant implications for capacity building of surveillance actors in order to improve early case detection and response.

Keywords: Mpox; Symptomatology; Outbreak; Surveillance

References

  1. Austin-Egole IS., et al. “Insecurity and the Pauperization of Residents of Owerri in Imo State, Nigeria: an Empirical Assessment”. European Journal of Social Sciences Studies 7.3 (2022): 36-61.
  2. Bunge EM., et al. “The changing epidemiology of human monkeypox—A potential threat?”. A systematic review. PLOS Neglected Tropical Diseases 16.2 (2022).
  3. Di Giulio DB and Eckburg PB. “Human monkeypox: an emerging zoonosis”. Lancet Infect Dis 4.1 (2004): 15-25.
  4. Ousmane Faye., et al. “Genomic characterisation of human monkeypox virus in Nigeria”. Lancet Infect Dis 18.3 (2018): 246.
  5. Eskild Petersen., et al. “Human Monkeypox Epidemiologic and ClinicalCharacteristics, Diagnosis, and Prevention”. Clinical Infectious Diseases 33 (2019): 1027-1043.
  6. Eteng WE., et al. “Notes from the field: responding to an outbreak of monkeypox using the one health approach — Nigeria, 2017-2018”. Morbidity and Mortality Weekly Report (MMWR) 67.37 (2018): 1040-10411.
  7. Fenner F., et al. Smallpox and its eradication Vol. 6 (Geneva: World Health Organization) (1988a).
  8. Fine PE, Jezek Z and Grab BDH. “The transmission potential of monkeypox virus in human populations”. International Journal of Epidemiology 17.3 (1988): 654-650.
  9. Gromyko AI DM. “Results of an investigation of a case of monkeypox in Nigeria [French]”. World Health Organization (1979).
  10. Hoff NA., et al. “Evolution of a disease surveillance system: an increase in reporting of human monkeypox disease in the democratic republic of the Congo, 2001-2013”. Int J Trop Dis Health 25.2 (2017).
  11. Hutin YJ., et al. “Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997”. Emerging Infectious Diseases 7.3 (2001): 434-438.
  12. Jezek Z., et al. “Human monkeypox: confusion with chickenpox”. Acta Tropica 45.4 (1988): 297-307.
  13. Jezek Z., et al. “Human monkeypox: secondary attack rates”. Bulletin of the World Health Organization 66.4 (1988): 465-470.
  14. Kara N Durski., et al. “Emergence of Monkeypox - West and Central Africa, 1970-2017”. MMWR Morb Mortal Wkly Rep 67.10 (2018): 306-310.
  15. Khodakevich L., et al. “The role of squirrels in sustaining monkeypox virus transmission”. Tropical and Geographical Medicine 39.2 (1987): 115-22.
  16. Kumbhar N and Agarwala P. “The lurking threat of monkeypox in current times”. Indian Journal of Medical Microbiology 40.4 (2022): 475-479.
  17. Marennikova SS., et al. “Isolation and properties of the causal agent of a new variola-like disease (‎monkeypox)‎ in man”. Bulletin of the World Health Organization 46.5 (1972): 599-611.
  18. Nigeria Centre for & Control D. “National Monkeypox Public Health Response Guidelines”. In Federal Ministry of Health (2019).
  19. Osadebe L., et al. “Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo”. PLoS Negl Trop Dis 11 (2017): e0005857.
  20. Petersena Eskild., et al. “Monkeypox — Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era”. International Journal of Infectious Diseases 78.2019 (2018): 78-84.
  21. Quiner CA., et al. “Presumptive risk factors for monkeypox in rural communities in the Democratic Republic of the Congo”. PLoS ONE 12.2 (2017): 1-14.
  22. Sklenovská N and Van Ranst M. “Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans”. Frontiers in Public Health 6 (2018): 241.
  23. WHO. World Health Orginization. Monkeypox outbreak: Update and advice for health workers (2022).
  24. Yasuo Ichihashi MO. “Epitope Mosaic on the Surface Proteins of Orthopoxviruses”. Elsevier Monkeypox Information Center 163 (1987): 133-l44.
  25. Z Jezek., et al. “Four generations of probable person-to-person transmission of human Monkeypox”. American Journal of Epidemiology 123.6 (1986): 1004-1012.